Literature DB >> 9818549

HIV infection: how effective is drug combination treatment?

Z Grossman1, M Feinberg, V Kuznetsov, D Dimitrov, W Paul.   

Abstract

The rate of decline of plasma HIV RNA in patients treated with anti-retroviral drugs has been postulated to reflect the half-lives of previously HIV-infected cells. Here, Zvi Grossman and colleagues argue that the observed decline is explained by the kinetics of ongoing infection cycles. Residual cell-to-cell infection that becomes increasingly difficult to block could stabilize cellular provirus reservoirs.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9818549     DOI: 10.1016/s0167-5699(98)01353-x

Source DB:  PubMed          Journal:  Immunol Today        ISSN: 0167-5699


  13 in total

1.  An in vitro rapid-turnover assay for human immunodeficiency virus type 1 replication selects for cell-to-cell spread of virus.

Authors:  S Gummuluru; C M Kinsey; M Emerman
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

Review 2.  The role of telomerase expression and telomere length maintenance in human and mouse.

Authors:  N P Weng; R J Hodes
Journal:  J Clin Immunol       Date:  2000-07       Impact factor: 8.317

Review 3.  Latency in human immunodeficiency virus type 1 infection: no easy answers.

Authors:  Deborah Persaud; Yan Zhou; Janet M Siliciano; Robert F Siliciano
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

4.  On the extinction probability in models of within-host infection: the role of latency and immunity.

Authors:  Ada W C Yan; Pengxing Cao; James M McCaw
Journal:  J Math Biol       Date:  2016-01-09       Impact factor: 2.259

5.  A parameter sensitivity methodology in the context of HIV delay equation models.

Authors:  H T Banks; D M Bortz
Journal:  J Math Biol       Date:  2004-12-20       Impact factor: 2.259

6.  Short-term measures of relative efficacy predict longer-term reductions in human immunodeficiency virus type 1 RNA levels following nelfinavir monotherapy.

Authors:  J Mittler; P Essunger; G J Yuen; N Clendeninn; M Markowitz; A S Perelson
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

7.  Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy.

Authors:  Steven A Yukl; Amandeep K Shergill; Kenneth McQuaid; Sara Gianella; Harry Lampiris; C Bradley Hare; Mark Pandori; Elizabeth Sinclair; Huldrych F Günthard; Marek Fischer; Joseph K Wong; Diane V Havlir
Journal:  AIDS       Date:  2010-10-23       Impact factor: 4.177

Review 8.  Modeling HIV persistence, the latent reservoir, and viral blips.

Authors:  Libin Rong; Alan S Perelson
Journal:  J Theor Biol       Date:  2009-06-17       Impact factor: 2.691

9.  Continued production of drug-sensitive human immunodeficiency virus type 1 in children on combination antiretroviral therapy who have undetectable viral loads.

Authors:  Deborah Persaud; George K Siberry; Aima Ahonkhai; Joleen Kajdas; Daphne Monie; Nancy Hutton; Douglas C Watson; Thomas C Quinn; Stuart C Ray; Robert F Siliciano
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

10.  Exploring the effect of biological delays in kinetic models of influenza within a host or cell culture.

Authors:  Benjamin P Holder; Catherine A A Beauchemin
Journal:  BMC Public Health       Date:  2011-02-25       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.